...as in half hour?
Printable View
...as in half hour?
Remember BLT?
What were your initial reason for PEB? Do they still hold? Can you afford it? What are the alternatives?
Actually I just mentioned it because I recall my great, great great grand-pappy telling me about him when he had steam-powered wireless ;)
As for BLT - one of my f***-ups but only cost a few grand so no real damage :-( Hopefully someone else will be able to advise you re PEB.
Good luck.
Hancocks I think the prospectous requirements for a nissue to existing shareholders only is a lotless.
I'm not a boffin, so this is really just for discussion, but I posted this on the other PEB thread yesterday:
I'm not brave enough to hold this stock, but it really is starting to look quite promising. On the bladder cancer diagnostic, it is worth comparing to Matritech product NPM22 Bladderchek. This is in a strong growth phase and producing revenue of around $US1.8m in the last quarter. The accuracy is not clear, but seems like it may be slightly less than what PEB are claiming. Bladderchek makes up the major part of Matritech revenues and Matritech is currently trading on a Price/Sales ratio of close to 3.5.
PEB are behind in timeline and would need various approvals to get to this point, so probably another 3 years away. But (big assumption) if they could generate similar revenues, and P/S would make the market cap around $36m...
That does not take into account the gastric cancer diagnostic or the possible therapeutics.
However, there is alot of competition in these areas world wide, plus regulatory hurdles and development costs to get through, so the risk is high.
Compared to listed biotech companies working in similar fields, I suspect PEB are very under-valued. In which case the rights issue is a great opportunity to establish a holding very cheaply. New revenue from developments within the next financial year seems very quick too. However, I believe there are alot of companies working on targetted cancer therapeutics and diagnostics and the majority will not end up being the commercial winners. So I would put it at the very high risk end of the investment spectrum and would not be investing money I couldn't afford to lose.
At the AGM, did they provide an explaination on why the Annual Report was late?
Have to say, that after posting here last, I went looking for the Medigen site - the company they are supposed to partnering with. The web-site did not appear to have been updated since early 2004... They did not have any investor info on the site or media releases. It did not appear that they have any commercial products (well at least in early 2004). Now, maybe I've missed something, but it did bother me that if PEB had something, they should be able to find a fairly "strong" company to partner them in it...
Just thought I should post that here to balance out my earlier post...
Another one where the old thread is stuck in the snitz forum.
Anyway, what is up with PEB this morning? No action for months and now a steady string of small buyers prepared to pay up. Was there a news article?
Lizard mon, a positive report on the business tv this morning mon. Something about they can test for certain types of cancer from a urine test mon.
There could be some more good news from PEB in the coming months.They should have their funding in place by the end of the year to carry them through to commercialisation.There may also be some good news regarding the completion of the gastric cancer diagnostic and possibly a licensing agreement.
There was also a positive article in the ODT on 31/8/07 following the AGM.
Mr. Tindall is a shareholder and he didn't turn up at the AGM for the tea an biscuits, this is why patience and following the smart money pays off.
That ASB Business TV item this morning left me with the impression that they have 4 tests ready to start selling. I thought "whaaaat? how did that happen so quick", having not checked on their progress for some months.
Didn't have time to follow up yet and find out what's happening.
Suspect I have got the wrong impression from the TV item. Their web site still says 3 test ready for clinical trials in 2007. Mmmm, reporters!
But I did have a minute to check depth in the morning and then see it broaden by this afternoon.
Sounds to me like your going to buy in, I've got a few had them for ages, they did get up to 17 cents awhile back they just shot up and then as quickly dropped again.
Alongside Tindall are some other interesting names now on the share register.Hubbard,Baines.Todd,Masfen.
It will be interesting to see what names appear after the capital raising.
Barney, I don't think their interests have changed. I think most (all?) of them are holdings that were previously via NZ Seed Fund (refer notice for PEBCA in Jul 2003). They distributed their shares back to individual unit holders in Sept 2006. Might be wrong there though?
I have a small parcel of PEB in my collection of "tiny little biotech holdings that seem cheap". I think yesterday was the first day my overall collection had been in the black since I started it! :eek:
Heres another one that will disappear over the horizon in foreign investors pockets, thats the way it goes with anything this country has thats any good just like the NZI advert says someones always stealing ya stuff.
It seems a brave move to announce the spp at approximately current market price and above the recent lows (and bid). A good move to my mind, since on these tiny cap shares, a low issue suggests desperation and can spiral down the price. No reason for that to occur in this case, so lets hope they can get the issue away to shareholders - it's a big dilution with $5.7m to be raised on a $10.1m market cap.
Lots of good things happening at PEB, but no certainty yet and a while till the extent of likely revenues can be gauged.
Yes,still a way to go for PEB Lizard but heading in the right direction.
It would help the spp if the company could release some positive news between now and the end of December.A licensing agreement for the gastric cancer diagnostic or some details regarding the private share placement would help.
I'll wait untill near the end of December to see what happens before taking up the offer.
I notice on the PEB website and on the Seek job search website that PEB have been advertising for a Bioinformatician.("Pacific edge is expanding it's bioinformatics team").
Seek is also advertising another job at PEB.A Relationship Development Manager-China.
They must have secured some funding from somewhere besides the spp.I wonder if there will be any news before the close off date for the spp?
Crazy time of year to send out an spp. I can't decide whether they are just terrible salespeople or they don't want shareholders to actually take up the shares - with price and timing making it so uncompelling!
This company seems to have little drive to commercialise its research. Its just a big tit for some Dunedin scientists to maintain their lifestyle. I wont hold my breath regarding the projected revenues in a year's time
You maybe right but they are not the only ones look around they are a few, funnily enough they are quite a few around Dunedin.
I notice that in the recent capital raising Peter Masfen raised his shareholding to 12% and the ACC have purchased a 5% stake.The ACC stake is small bananas in the grand scheme of things but interesting given the state of the listed biotechs at the moment.
I was surprised to see ACC popping up at this point in time...
ACC seem to own virtually everything on the NZX...
....anyway, could be an okay time to own PEB if they were to actually meet their timeframes for completion of the bladder cancer assay clinical trial in the next 6 months (with first revenues expected "soon" after). Full year report due soon and will see how they are progressing.
Web-site is a disappointment with no 2007 report or interim report available there - given they are supposed to be going to the "electronically available" option, this seems a little remiss.
...something I posted on another forum a few months ago in regard to the fariness of the $12m market cap relative to market prospects...
Quote:
Actually, also of interest in this regard is the progress of Matritech who were the major US producer of the Bladderchek test. Matritech was expecting FY07 revenues of around $US15m, coming largely from this business. However, the company continued to report quarterly losses and the assets were recently sold to Inverness Medical Innovations for $US36m. Matritech has since filed for dissolution. The sale and dissolution was expected to realise $US10 - $US12m for shareholders.
How does the PEB product differ from what Matritech did?
My understanding is that the PEB product contains a prognostic as well as diagnostic aspect. But I am not entirely sure. I'm also guessing it is a more expensive test. Not an expert in these things.
Of course PEB also have the colo-rectal and gastric tests in pipeline plus early stage products and IP.
Thanks for the points of difference... :)
I have finally been able to lay my eyes on the annual report, via the companies office web-site where it has now been lodged.
Last year, I recall seeing the notice advising that they would now be not issuing paper copies of the report except where requested and the report would be available on-line. That seemed fine until I received the "shareholder password" in the mail - a few weeks before the report was due to be put on line. Of course, it went into my totally safe filing system :eek: - and was never found again.
Anyway, I am still puzzled as to why a listed company would password protect its annual report on its web-site - I thought listed companies were required to provide potential investors with a copy of their annual report on request anyway? Even if that is not the case, the report is now available (one month later) on the companies web-site, so why the secrecy?
The directors report opines on the company's flagging share price that:
Some responses:Quote:
The domestic capital markets appear not to recognize the commercial potential of these medical device stocks.
- Apart from not making their annual report freely available, the company seems not to have published an AGM speech last year or any other form of analyst presentation. If the market potential is to be recognised in the share price, then it is up to the company to explain it to the market.
- Any company which anticipates raising new capital and yet does not attempt to make sure the market has a chance to fairly assess value is not acting in the best interests of existing shareholders. This additional risk factor only serves to further reduce any value attributed to existing shares.
- Believability needs to be maintained and this means realistic/conservative timeframes being put forward. For instance in the 2006 report, the bladder cancer clinical trials were about to start and were expected to take 18 months; in 2007 the trials were supposedly underway and expected to be completed by the second quarter of 2008 and now the report says the the trial has begun and is expected to be completed by mid-2009. The lack of other updates or explanations for this slippage means that anything else the company writes can only be read with scepticism.
- If the company is so cheap, where are the merger and takeover offers? No one shareholder appears to hold a blocking stake, although possibly there is some crossover of interests which protects the company?
The company provides some great info in its annual report which continues to be encouraging in terms of products and potential. However, they also indicate that each programme will require one clinical trial at $1m per trial - suggesting further capital raising will likely be needed unless they obtain significant licensing fees in the near future. I would like to see them make more effort to communicate the potential to NZ investors.
Note that the 2008 annual report contains references to NMP22 which is the Matritech test. PEB claims early indications that their test will be 90% accurate for stage one bladder cancer compared to 47% for NMP22. They also intend to test against NMP22 in the clinical trial.
I've also had a look at Genomic Health (Nasdaq GHDX) as a comparison raised by PEB for their breast cancer assay. It looks as though they raised over $53m in their float in 2005 to support commercialisation of their breast cancer assay. They use a 21 gene panel, so a little more complex than PEB's bladder cancer with 4 genes. In 2005, their revenue rose to $5m from $0.3m a year earlier, then $29m in 2006 and $64m in 2007. This seems to be nearly all on the back of their one commercial diagnostic. The most recent quarterly report shows revenues of $23m for three month period - however, the company still managed to report a $7m loss, with the cost of sales and marketing being a massive $12m. In fact, the annual losses have barely changed over the years, from a loss of $25m in 2004, through to a loss of $27m in 2008. While this can be largely attributed to the cost of sales and marketing and expensing of R&D, it is clearly not a rate of loss that a small NZ company could expect to maintain. Market cap of GHDX is currently $635m, with significant net cash.
I think the comment that the capital markets don't understand PEB is incorrect. I think they do and is reflected in the share price. These guys have forgotten they are a business with the objective to make money, the sooner the better. I feel that this company is managed for the benefit of management and researchers rather than shareholders. When is all this research going to be commericialised and we see some revenue?
Dubdee,
World-beating, valuable technology is rarely developed on a shoestring budget. And when it is, getting it to market ahead of emerging competitors is an even larger (financial) challenge. There is a negative feedback loop in NZ technology investment which is not helping. It goes like this:
- Investors are dubious about the odds of investment success on early-stage technology - therefore they apply a high risk premium in their valuations (lower valuation)
- Low valuation applied to company reduces the potential capital that can be raised and therefore limits the speed of development, increasing time till profitability and reducing the magnitude of forecast profits. It also increases the dilution of existing shareholders that occurs while the company is in capital-raising stage. Both these factors further reduce the underlying valuation of existing shares.
- Lower share valuation means next round of investment requires even more dilution and further slowing of speed to market. Share price goes down with each round of capital raising.
- Investors become even more dubious about their odds of making money on early-stage technology investments.
There are other negative feedbacks in there as well - liquidity being one. Loss of (or inability to attract) good management due to lack of investor support may be another.
While the excessive optimism of the dot.com era was not healthy, this "kill-it-off-before-it-dies" pessimism of the Australasian markets is self-fulfilling.
I tend to agree with your comments Lizard,especially in regards to PEB and the forcasts they have made concerning trial completion dates and capital raisings.
I guess one positive is the fact that the largest shareholders have recently put more money in,including Peter Masfen who is now the biggest shareholder.
To get some positive sentiment building towards the companies outlook they will actually have to meet some of the dates they have forcast for completion of trials and product developement as set out in the annual report.They will need to show that they have a product ready for market and that it can generate revenue.Untill then the shareprice won't move.
I think the products they are developing have huge potential,especially the gastric cancer test.We may get a better idea of how things are progressing with the agm to be held this month.
Gone from 8cps to 13cps. Did we accidentally ramp this? :confused::o
Early this year I remember, whilst trolling the internet,coming across a couple of lines in an article which quoted CEO David Darling.The article was talking about the difficulties of raising capital in NZ.From what I can remember there were a couple of lines where David Darling mentioned how difficult it was to raise capital in NZ and that PEB may look at listing on offshore markets such as London or in the US.I've tried to find the article but to no avail.
When reading the annual report and coming across the line that Lizard mentioned re the capital markets not understanding the potential value of PEB I recalled the above mentioned article.Should they strike a licensing deal with a European or US company listing offshore may be someting they look at.It seems a slightly unusual thing to say in an annual report so maybe it's a hint to where they are looking.
Trouble is not many NZ companies have covered themselves in glory by listing offshoe and it would be an expensive exercise for a small biotech.But then again if they had an offshore partner.
Hmmm. Years ago I posted advice that this was a company to avoid and someone shouted me down. My posting seems to have disappeared but my advice remains the same. I had been informed by someone whose advice I respect that, if my recollection is correct, the predictive model they were using tended to greatly overestimate the tests effectiveness.
I see the Ludwig Institute have announced on their website the joint development with PEB of the prototype prognostic test for the progression of aggresive stage III melanoma.The test has 85% to 90% accuracy.
It would appear that the initial validation tests have been completed.The next stage should be the clinical trial which was mentioned in the annual report.I guess there will be more detail at the agm.
Hi Barney, here's some more related links - the first to an article on Genome Web and the second to the (abstract from the) actual publication in Clinical Cancer Research:
http://www.genomeweb.com/issues/news/148865-1.html
http://clincancerres.aacrjournals.or...act/14/16/5173
Cheers Lizard
You never know,this time next year PEB could actually have three products ready for market.
The bladder cancer diagnostic,colorectal cancer prognostic,and the melanoma prognostic.
Genomic Health is working on colon cancer too - and with a slightly bigger budget I would think. Gastric cancer would be the one to nail!
Just recently aware of this puppy. Any recent thoughts out there?
Looks risky, but maybe worth a dabble??
I sold out of PEB. Has been a good hold through the turbulent GFC, but when I bought, I think the market cap was around $12m and it is now about $36m. Still a bit of uncertainty and likely growing pains as they go commercial. The potential may be there, but I'm wary that commercialisation is often a disappointment in the first few years.
There are so many "cheap" stocks available in NZ at the moment that PEB no longer looks so attractive by comparison.
Best wishes to holders. I will continue to follow with interest.
I have been watching since my last post - at 11c. Never bought in and obviously have rued this. The price strengthened up to about 25c, and has recently dropped back to about 17c.
But the big jump Monday/Tuesday was probably caused by this and a lack of liquidity.
http://www.stuff.co.nz/sunday-star-t...e-in-7b-market
Still interested if the price is right. Know one person invloved in the company and fairly serious person, who I would rate.
Price up today on this article: http://www.nzherald.co.nz/business/n...0619619&pnum=0
____________________________________
Just aim to get in at an average price then.
If you have $10k, buy 2k @ 35 cents, put 2k on the market at the best bid, you might pick them up for 30 -33 cents.
And wait for the trial results, if they are negative the price might go back to 15 -20 cents, and you only lose out on the 4k you invested, and you can buy another 2k at 15-20 cents.
If the the results are positive, and price goes up, you have a little skin in the game, and you accumulate more on the way up.
This is all based on the fact that you think long term the stock is fundamenatlly sound investment for your risk level.
______________________________
Commercialisation of Pacific Edge's Bladder Detection Test
https://www.i-search.nzx.com/blobs/N...000-113259.pdf
Pacific Edge announces Cxbladder performance at the Australian and New Zealand urologists scientific meeting in Perth, Australia.
22 February 2010
Pacific Edge announced the clinical trial performance of the Cxbladder, test in Perth on Monday 22nd of February. Peter Davidson, a renowned New Zealand urologist and the lead clinical investigator in this research, presented the scientific performance of Cxbladder to the Australasian urologists and medical professionals at their Annual Scientific Meeting. The scientific meeting hosted 600 delegates with urologists from New Zealand, Australia, US, Singapore, South Africa, United Kingdom, Ireland, Indonesia, Hong Kong, Malaysia and Papua New Guinea.
The Company’s bladder cancer diagnostic technology, Cxbladder, enables the early detection of bladder cancer from a small volume of urine. The presentation in Perth reported on the performance of Cxbladder, the new commercial product developed from the clinical trial data. Cxbladder showed an approximate overall sensitivity that was 30% better than urine cytology and 40% better than the competitor test NMP22. Its performance was most notable for the detection of tumours of high grade, and middle and late stage, where it correctly identified greater than 96% of cases with 85% specificity. These tumours are of particular concern to urologists and the tests high performance provides an opportunity to improve patient outcome and lower overall costs of treatment.
The Company, as part of its roll-out in the US and Europe, has plans in place for further studies that will have the dual purpose of providing further validation data and also engaging specific key medical and urological opinion leaders who will be vital to a successful launch in new markets.
This non-invasive test is expected to provide general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. After additional clinical testing, Cxbladder is also anticipated to be used for monitoring patients for recurrence following treatment.
Pacific Edge completed recruitment of patients for the bladder cancer clinical trial in late 2009 and analysis of the data was completed in February. The data analysis on almost 500 patients from NZ/Australia shows that the Company’s bladder cancer test has met its clinical end points and performs significantly better than all of the benchmark tests.
Bladder cancer is one of the most common cancers in Western society. In Australasia, bladder cancer is the 5th most common cancer among men and the eighth most common cancer overall. On a global basis there are 365,000 new cases annually and 47,000 deaths.
Bladder cancer has the highest total medical costs of any cancer driven in part by the very high recurrence rate (50-90%), with approximately 15-30% of these recurring as later stage tumours. The surveillance of patients who have been diagnosed with bladder cancer extends for at least five years from the time of first diagnosis. Surveillance is currently carried out by urologists using invasive cystoscopy often accompanied by one or more cytologies. The Company’s test is designed to replace cytology and to also be used as an adjunct to cystoscopy. Its use is predicted to not only improve the quality of surveillance but also lead to a decrease in the frequency of cystoscopies.
The Company is progressing the commercialisation of this product to Australasian urologists through its Dunedin based laboratory. The Company is currently developing its commercial laboratory to provide a dedicated service and would expect that this will be completed within the next few months and the test offered commercially in May 2010.
Commercialisation of Cxbladder is planned to follow-on in Singapore, USA and Europe by providing services to physicians and urologists through a centralised service laboratory strategy in each geography. Pacific Edge anticipates partnering in several of these locations using the services model being developed in the Australasian market and negotiations are currently underway with potential commercial partners in the US, Europe and Australasia.
The Company has recently been awarded patents in New Zealand and Singapore for its bladder cancer diagnostic technology and the Company anticipates the issue of these patents in other targeted countries to follow over the next 12 to 24 months.
Pacific Edge Biotechnology Ltd, (PEB), is a Dunedin based biomedical company developing and commercialising technology for cancer detection and management.
even dropped back to 25c this has made as much as resteraunt brands and feels like a bomb about to go off.
NZX Release Pacific Edge (PEB)
Pacific Edge advises the successful completion of the European clinical trial of our prognostic gene signature for colorectal cancer. This is a significant commercial milestone for the Company. The clinical trial results for Pacific Edge’s gene signature will be presented at the annual scientific meeting of the American Society of Clinical Oncology (ASCO) by our European licensee in early June in Chicago. Pacific Edge’s colorectal cancer prognostic gene signature is the second commercial product for the Company and it joins the Company’s recently launched bladder cancer detection test Cxbladder.
Europe is the second largest healthcare market in the world after the US, representing approximately 30% of global health care spending.
Colorectal cancer has second highest incidence of all cancers creating a large impact worldwide with over 1.1 million new cases annually. Colorectal cancer has a particularly high incidence in Japan, Australia, New Zealand, Europe and North America. It is anticipated that this year over 530,000 people globally will die from the disease.
This new product for the prognosis of colorectal cancer is targeted to meet a large unmet clinical need for patients diagnosed with colorectal cancer. Pacific Edge’s prognostic gene signature identifies patients with stage II or III colorectal cancer whose disease is aggressive, likely to recur after surgery and who would benefit from additional treatment. The identification of those patients at greatest risk represents a new tool for clinicians and effective use of this tool by clinicians could be expected to lead to better treatment and more lives saved.
Pacific Edge’s colorectal cancer prognostic gene signature is the second commercial product for the Company and it joins the Company’s recently launched bladder cancer detection test Cxbladder. Cxbladder is a fast, accurate, non-invasive assay that accurately measures the activity of five genes from a small sample of the patients’ urine to diagnose bladder cancer.
Pacific Edge is a biomedical company specialising in the development and commercialisation of diagnostics and prognostics for cancer. The Company is also actively working on the research and development of products for gastric cancer, endometrial cancer and melanoma.
Thanks for finding the thread .. Phaedrus.
Will be interesting if this news (released at close of market yesterday) moves the share price.....on the basis of bouncing of the support at 20c four times. ( in the last several weeks). and the increased volumn .. I purchased on Monday and last week at 22c.
Would expect a price spike... but the markets are currently not buoyant. 6 hours will tell.
Closed at 32c ..up over 50% in the last 10 days...............Would a real chartist (as opposed to a rank amateur like myself) be prepared to voice a opinion .on where from now............ thanks.
Pacific Edge Announces Successful Completion of Colorectal Cancer Prognostic Clinical Trial
Clinical Results Presented Today at ASCO 2010
CHICAGO, IL (June 4, 2010): Pacific Edge (PEB) a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately. PEB’s European licensee, Signature Diagnostics (SDX) completed the clinical trial and will present the results at the annual scientific meeting of the American Society of Clinical Oncology in Chicago on the 4th of June.
Chief Executive Officer David Darling stated that the conclusion of the European clinical trial, was a significant commercial milestone for Pacific Edge. “This prognostic gene signature for colorectal cancer is our second commercial product, and joins our bladder cancer diagnostic assay, Cxbladder™. Cxbladder™ is a fast, non-invasive assay that measures the activity of five genes from a small sample of the patient’s urine to accurately diagnose bladder cancer.”
Pacific Edge Chief Scientific Officer, Parry Guilford commented that the company’s prognostic gene signature will meet a large unmet clinical need for patients diagnosed with stage II and stage III colorectal cancer. “Our prognostic gene signature identifies patients with stage II or III colorectal cancer whose disease is aggressive, likely to recur after surgery, and who would benefit from additional therapy”.
Pacific Edge granted a European exclusive licence for its new cutting-edge prognostic gene signature for colorectal cancer to SDX in late 2006 with commercialisation pending a sucessful completion of the clinical trial. Europe is the second largest healthcare market in the world after the United States and represents around 30 per cent of global health care spending.
Colorectal cancer has the second highest incidence of all cancers in the world, with over 1.1 million new cases diagnosed annually. It has a particularly high incidence in Japan, Australia, New Zealand, Europe and North America. This year more than 530,000 people around the world are expected to die from the disease.
Did any one go to the AGM or have news from the AGM
I did'nt get to the AGM but there will probably be something about it in the Otago Daily Times tomorrow or Monday.
Thanks for that update Hancocks...was tempted to go down.. but living in Hastings...
Couple of questions if I may..
A/ From a commercial.. point of view.. Did you get the vibe.. that the products would make the company profitable in the next year or so.
B/ Any hint of new product/tests ..or value adding in the next 6 months to a year.
Thanks for that.
Cheers.
If they believe they could be cash positive, and it comes true, it might be time to get in.
The New Zealand Trade and Enterprise website has a interview clip with David Darling which is quite interesting.
What up with peb? Sellers have disappeared currently price 20 cents buyers at 20 sellers at 34. Any new coming?
Anyone know where I can get a copy of the 2010 annual report?
Normally, I would have said the Companies office, but it doesn't look like it is available there... google sometimes finds the backdoor though - try this:
PEB AR 2010
PEB - HY sep 2010
Perfect, thank you!
I think they will need another capital raising before the cashflow comes good. But Healthscope is a major player in labs in Oceania, they have already taken over some NZ labs eg Gribbles vet pathology but PEB is too illiquid for a takeover ... but then i thought that of AFFCO.
Never say never They are some big players watching this stock.
Does the book build mean some of them are taking a stake?
......sounds like a well balanced and fair (unlike WDT) capital raising proposal......I'll be taking up my full allocation plus some if possible. I dont see any huge risks attached to this small company and more than happy to support and enjoy the ride with a true Kiwi hi-tech company. If this is a successful cap raising they will have more cash than they know what to do with for some time.....I think $5.1m plus $16m?? Roll on PEB!!
wooow......big buyer at 20c just pulled the price back 6% (but not for long by the look of things).......someone's got confidence in this co. besides myself (stephen tindall "topping up") ??...........
A couple of things of interest in an article about PEB in todays NBR.
David Darling mentioned that the initial share offer to institutional and habitual investors in the latest capital raising had been significantly oversubscribed and that the demand will flow on through to the tradeable rights which will come from the rights issue.
The company expects to have US licenses and to be market ready in March 2013. The first US customer has a private practice in New Jersey that has 120 urologists in it, about three times as many as there are in NZ.
I hope to make the trip south to attend the AGM on the 25th. Should be interesting.
........all sounds good Barney. Enjoy the AGM and please keep us posted. Exciting prospects for an ethical cutting edge co.
The annual meeting held yesterday was a low key but interesting affair. Much of what was presented was information which has already been presented to shareholders over the last few months. However, there were some interesting points.
Healthscope and PEB will begin marketing cxbladder in Australia in about four weeks time.PEB expects Oryzon to start marketing in Spain and Portugal some time in October.
Singapore is likely to be the next country that PEB targets. Patents have been issued in Singapore, it is close to other Asian markets, is English speaking, and has tax agreements with NZ which means they are not taxed twice.
The recent share issue to institutions was 1.6 times over subscribed so augers well for the capital raising.
The general message from the company is that things are progressing well and it has been a satisfying year, especially on the science front.It will take a bit of time and marketing effort to get sales cranked up, with Colin Dawson making the point that medical specialists are naturally conservative in nature especially when introducing new products.David Darling commented that Parry Guilford was close to finalising a peer reviewed paper for release to the medical profession which should help in getting cxbladder into the marketplace.
Interesting article about Pacific Edge in http://unlimited.co.nz/unlimited.nsf...breaks-through
Hope they still hold enough cash to proceed its plan till the end of the year.Quote:
Based in Dunedin, New Zealand, Pacific Edge Diagnostics, Ltd., a leading developer of cancer diagnostic and prognostic technology, plans to open its first US franchise to market the company's bladder cancer detection test, Cxbladder(R), to urologists in the United States by the end of the year.
http://www.fox43.com/news/wpmt-new-c...0,910457.story
An interesting video about the planning US lab.
Zs......Im pretty sure there's plenty of cash in the coffers for these and further developments?
About $20 million which should last 3-4 years (last report expense $3.5m). Shareprice seems to have a solid bottom at 19c. The next year should be key as to how cx bladder is accepted in the new markets. Not much on sales yet - NZ & Aus starting now and states to come in late 2012. Quality partners should help eg Healthscope, Penn state uni.
Strong $NZ so good time to be investing o seas. Can't see much sign of broad institutional support yet - no AMP or govtsuper or ACC on the register last ann report.
http://www.odt.co.nz/news/business/2...dy-us-roll-out
Unfortunately I did'nt get to this years meeting but I spoke with a mate last night who attended and it sounded very positive. He said the fitout of the US lab is running on schedule and on budget. He also noted that during the meeting David Darling mentioned that they were working on some new deals and these would hopefully be announced in the not to distant future.
All in all things look good for the future with the US business still looking to be up and running in March 2013.
Is that intra day up to 32 c ... and volume like never before....
I suspect someone must be slowly accumulating as the share price kepts increasing slowly. Every time I think about selling a few the price goes up again and I stick them back in my pocket. It would be nice to know what is going on. Still kicking myself for selling out of ATM to soon after holding the shares for years so I dont want to do the same mistake again
Spike
According to PEB the price per test in the US is likey to be between US$500 and US$800. The test in Australia is AU$240 and in NZ $320.
http://www.odt.co.nz/news/business/2...-ready-operate
Looks like they are happy with the initial revenue figures.
:) Always good to see PEB in the paper http://www.nzherald.co.nz/business/n...ectid=10841548
Anyone else got a bit more information/speculation on the joint venture with Harvard? Definitely couldn't hurt their reputation as they seek to fill those 260,000 orders.
P.s. My first post!! after months of devouring Sparky, PT's, Balance, Belgerions and co's wisdom and banter. Please be nice.
.......ALL THE TESTS AND EVIDENCE BASED RESULTS ARE AT HAND ALREADY......THUS IT SHOULD BE AN EASY SELL INTO THE US MARKETS. THE TIGHT KNIT COMMUNITY OF AMERICAN UROLOGISTS WILL BE WELL AWARE ALREADY (and possibly waiting with baited breaths)......LAUNCH DAY WILL BE WELL ANTICIPATED AND I IMAGINE ORDERS WILL BE THERE ALREADY.........THAT'S THE WAY THINGS WORK THESE DAYS. WISH I HAD BOUGHT MORE NOW........BUT ISNT THAT JUST THE WAY!!
.......AGREED SPARKY......but then if US doctors are really THAT profit focused they will inevitably run with the "cheaper" and hopefully more reliable option (CxBladder) and be able to crank their profits accordingly!! As far as future SPs go I'd be more than happy with the former($1/share)......but all a bit early to be getting that excited. Very achievable though but steady as she goes is what we all want ah??
...cystoscopy - a needle inserted into one's urethra (shudder).[/QUOTE]
Its not a needle.
A cystoscopy is a direct visualisation of the bladder by flexible telescope. Think more the diameter of a ball point pen.
Thank god for anaesthetics. ;)
Since the shareprice has moved up following the annual meeting there have been a number of articles about PEB in the media. It goes to show how lazy most jurnos are when it comes to reporting on listed companies. Apart from the ODT, there have been few articles in the media since PEB was listed over 10 years ago. Most jurnos don't know much about the company and the main reason for the recent reporting on it seems to be that the shareprice has increased, yet the company has just been going about it's business and progressing with Cxbladder to a point where it is now entering markets.
Another article recently described PEB as a " start up company." That's after the company has been around for more than a decade.
I notice in the Chalkie article the author says the shares are overpriced but he does not say what price they should be valued at, which is pretty typical for a jurno these days.
I thought Chalkie wrote a very fair article.Tim Hunter [present Chalkie] is a very experience jurno and investor. Although prospects look excellent any investor who has invested in this sector in NZ,Aussie,US,or UK will tell you it is near impossible to value such a company.Many a fool has tried and failed.Hunter is no fool.